SCHEMBL3769008

SCHEMBL3769008

COc1ccc(OC)c(/C=C/C(=O)N2CCN(CC(=O)N3CCN(C4CCC4)CC3)CC2)c1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.49
JUN P05412 1/20 0.48
NFKB1 P19838 1/20 0.48
ALDH1A1 P00352 3/20 0.46
MAPT P10636 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
KMT2A Q03164 2/20 0.46
TSHR P16473 1/20 0.46
TDP1 Q9NUW8 1/20 0.45
HPGD P15428 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ACHE P22303 1/20 0.44
PTGS2 P35354 4/20 0.43
ABCG2 Q9UNQ0 1/20 0.43
PTGS1 P23219 1/20 0.43
CBX7 O95931 1/20 0.42
CDYL2 Q8N8U2 1/20 0.42
CDYL Q9Y232 1/20 0.42
MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3769019 1.00 RAB9A (0.49) RAB9AJUNNFKB1ALDH1A1MAPT
SCHEMBL3773289 0.93 KDM4E (0.51) RAB9AALDH1A1MAPTSMN1; SMN2KMT2A
SCHEMBL3773292 0.93 KDM4E (0.51) RAB9AALDH1A1MAPTSMN1; SMN2KMT2A
SCHEMBL3776062 0.90 TDP1 (0.44) RAB9AALDH1A1MAPTSMN1; SMN2KMT2A
SCHEMBL3776067 0.90 TDP1 (0.44) RAB9AALDH1A1MAPTSMN1; SMN2KMT2A
SCHEMBL3769113 0.89 TDP1 (0.45) RAB9AALDH1A1MAPTSMN1; SMN2KMT2A
SCHEMBL3769117 0.89 TDP1 (0.45) RAB9AALDH1A1MAPTSMN1; SMN2KMT2A
SCHEMBL3774586 0.88 HPGD (0.60) RAB9AALDH1A1MAPTSMN1; SMN2TDP1
SCHEMBL3774593 0.88 HPGD (0.60) RAB9AALDH1A1MAPTSMN1; SMN2TDP1
SCHEMBL3772235 0.86 TDP1 (0.43) RAB9AALDH1A1MAPTSMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 RAB9A 3824/4885JUN 3368/4885NFKB1 3477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.